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Introduction {#sec005}
============

Hematoma expansion (HE) is a predictor of poor clinical outcome in intracerebral hemorrhage (ICH) \[[@pone.0236196.ref001]\]. Contrast extravasation on computed tomography angiography (CTA), known as the "spot sign", is a validated predictor for HE. However, conventional CTA is limited by its "static" acquisition of images \[[@pone.0236196.ref002]\].

Dynamic CTA (dCTA) acquires a series of CTA images over a 60-second period. We have previously reported that dCTA captures a higher prevalence of spot signs than conventional CTA \[[@pone.0236196.ref003]\]. However, the specificity of the spot sign on dCTA for predicting significant HE was lower than that of the spot sign on conventional CTA \[[@pone.0236196.ref003]\]. This lower specificity may be due to a lower rate of expansion associated with "delayed" spot signs (i.e. spot signs that appear in later phases of image acquisition). In support of this hypothesis, a recent study reported that spot signs captured in earlier phases of imaging acquisition on conventional CTA had stronger associations with HE compared to spot signs captured in delayed phases \[[@pone.0236196.ref004]\]. Therefore, we hypothesized that the phase of spot sign appearance on dCTA may be a novel predictor of HE and clinical prognosis. In the current study, the primary objective was to describe the performance of the arterial versus venous phase of spot sign appearance in predicting HE. Secondary objectives were to explore total absolute HE, rates of contrast extravasation as a surrogate of spot sign growth, mortality, and functional outcome across phases of spot sign appearance.

Materials and methods {#sec006}
=====================

Ottawa Health Science Network Research Ethics Board (OHSN-REB) approved this study with a waiver of consent for data collection. We launched a prospective registry of consecutive patients aged ≥ 18 years who presented to the Ottawa Hospital, Ontario, Canada, with spontaneous ICH within 4.5 hours from symptom onset. All patients with symptoms of stroke presenting under 4.5 hours received a dCTA as part of a standardized code stroke process. Patients with known secondary causes of ICH such as trauma, malignancy, aneurysms, or arteriovenous malformations were excluded.

The dCTA acquisition protocol has been previously described \[[@pone.0236196.ref005]\]. Briefly, we obtained non-contrast CT images followed by dCTA acquisition using 320-row volume CT scanner (Toshiba Aquilion ONE^TM^). We acquired whole-brain angiographic images over a 60-second period: once at 7 seconds (used as a mask of subtraction) from the start of injection of contrast; then every 2 seconds from 10 to 35 seconds, followed by every 5 seconds to 60 seconds. An expert neuroradiologist (S.C.) blinded to follow-up scans and patient outcome determined the spot sign status \[[@pone.0236196.ref006]\]. We measured spot sign density using Quantomo Pro (Cybertrial, Calgary, AB). We estimated the rate of contrast extravasation as a measure of dCTA spot sign growth by calculating the slope of a time-density plot from the earliest point of spot sign appearance to the maximal contrast volume of the dCTA spot sign \[[@pone.0236196.ref003]\]. To classify the phase of spot sign appearance, we measured the maximum Hounsfield units (HU) of an arterial and venous structure in the plane of the dynamic spot sign in the hemisphere contralateral to the ICH at time of spot sign appearance \[[@pone.0236196.ref004]\]. We then categorized the phase of spot sign appearance into five acquisition phases: early arterial, late arterial, equilibrium, peak venous, and late venous phases, as previously published \[[@pone.0236196.ref004]\]. We pooled the groups into two phases, arterial and venous, for data analyses.

The primary outcome was significant HE defined as an absolute growth of ≥ 6 mL or a relative increase of ≥ 33% in parenchymal hematoma volume on follow-up CT head \[[@pone.0236196.ref007]\]. Patients underwent a 24-hour follow-up CT as standard of care at our institution. We measured hematoma volumes using Quantomo Pro (Cybertrial, Calgary, AB). Secondary outcomes included median total HE defined as the absolute difference in total blood volume (ICH and IVH) between baseline and follow-up scans, in-hospital mortality and poor functional outcome (mRS 4--6) at discharge.

Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of arterial and venous phases in predicting significant HE were calculated with 95% confidence intervals. We evaluated radiologic and clinical outcomes across phases of spot sign appearance using Mann-Whitney U test or Fisher's exact test, as appropriate. We used logistic regression to assess phase of spot sign appearance as a predictor of significant HE. All statistics were performed using SPSS v23 (IBM, Armonk, NY). We applied complete case analysis for primary analysis, and extreme case analysis for sensitivity analysis. In the worst-case scenario, missing values for significant HE were assumed negative in the arterial group and positive in the venous group, and vice versa in the best-case scenario.

Results {#sec007}
=======

We enrolled 83 consecutive ICH patients, 5 of whom were excluded due to secondary causes of ICH. There were 35 spot positive patients, of whom 27 appeared in the arterial phase and 8 appeared in the venous phase. Thirty patients were included for HE analyses, and 35 patients were included for the remaining clinical outcome analyses. 4/27 patients in the arterial phase did not have follow-up CT scans due to palliation (n = 2) and early mortality (n = 2), and 1/8 in the venous phase did not have scans due to palliation (n = 1). Cohort selection flow diagram is presented in [Fig 1](#pone.0236196.g001){ref-type="fig"}. Baseline radiological characteristics for each cohort are presented in [Table 1](#pone.0236196.t001){ref-type="table"}. No statistically significant differences in baseline characteristics were observed between the arterial and venous cohorts.

![Cohort selection flow diagram.\
ICH = intracerebral hemorrhage. dCTA = dynamic computed tomography angiogram. ICH = intracerebral hemorrhage. mRS = modified Rankin scale. CT = computed tomography. HE = hematoma expansion.](pone.0236196.g001){#pone.0236196.g001}

10.1371/journal.pone.0236196.t001

###### Cohort characteristics.

![](pone.0236196.t001){#pone.0236196.t001g}

                                                                                          Grouped Arterial Phase (Early + Peak)   Grouped Venous Phase (Peak + Late)   P Value
  --------------------------------------------------------------------------------------- --------------------------------------- ------------------------------------ ---------
  **Total N**                                                                             27                                      8                                    ** **
  **Demographics**                                                                        ** **                                   ** **                                
  Age (years)                                                                             79 (69.5, 84)                           82.5 (72.25, 88.25)                  0.56
  Male                                                                                    11/27 (40.74)                           4/8 (50)                             0.7
  **PMHx**                                                                                ** **                                   ** **                                ** **
  Ischemic Stroke or TIA                                                                  6/27 (22.22)                            1/8 (12.5)                           1
  Coronary Artery Disease                                                                 2/27 (7.41)                             0/8 (0)                              1
  PE/DVT                                                                                  4/27 (14.81)                            0/8 (0)                              0.55
  Intracerebral Hemorrhage                                                                2/27 (7.41)                             1/8 (12.5)                           0.55
  Subarachnoid Hemorrhage                                                                 2/27 (7.41)                             0/8 (0)                              1
  Subdural Hemorrhage                                                                     1/27 (3.7)                              0/8 (0)                              1
  Hypertension                                                                            14/27 (51.85)                           4/8 (50)                             1
  Diabetes Mellitus                                                                       5/27 (18.52)                            1/8 (12.5)                           1
  Atrial Fibrillation                                                                     4/27 (14.81)                            2/8 (25)                             0.6
  Congestive Heart Failure                                                                2/27 (7.41)                             2/8 (25)                             0.22
  Current Smoker                                                                          2/27 (7.41)                             1/8 (12.5)                           0.55
  **Medication Hx**                                                                       ** **                                   ** **                                
  Aspirin                                                                                 8/27 (29.63)                            2/8 (25)                             1
  Plavix                                                                                  3/27 (11.11)                            1/8 (12.5)                           1
  Warfarin                                                                                4/27 (14.81)                            1/8 (12.5)                           1
  Heparin                                                                                 2/27 (7.41)                             0/8 (0)                              1
  **Baseline Clinical**                                                                   ** **                                   ** **                                
  Premorbid mRS Score                                                                     0 (0, 1.5)                              0 (0, 2.5)                           0.59
  GCS Score[^a^](#t001fn002){ref-type="table-fn"}                                         14 (11, 15)                             14 (12.5, 15)                        0.68
  NIHSS Score[^b^](#t001fn003){ref-type="table-fn"}                                       14 (10, 18.75)                          12 (9.5, 17.5)                       0.49
  Systolic blood pressure (mmHg)                                                          178 (160.5, 187.5)                      177.5 (162.25, 198.75)               1
  Diastolic blood pressure (mmHg)[^c^](#t001fn004){ref-type="table-fn"}                   90 (78, 102.75)                         94 (82, 100)                         0.94
  Glucose (mmol/L)                                                                        6.6 (6.05, 9.3)                         6.55 (6.28, 7.33)                    0.86
  Platelets (x10^3^ cells / L)                                                            192 (162, 251)                          177.5 (158, 197.25)                  0.29
  INR[^d^](#t001fn005){ref-type="table-fn"}                                               1 (1, 1.2)                              1.2 (1.05, 1.5)                      0.19
  Creatinine (μmol/L)                                                                     77 (62.5, 95.5)                         76 (65.25, 90)                       0.95
  **Baseline Radiologic**                                                                                                                                              
  ICH Volume Baseline                                                                     35.53 (20.41, 58.25)                    21.81 (13.24, 51.64)                 0.53
  IVH Volume Baseline                                                                     0 (0, 0.79)                             0.9 (0, 2.91)                        0.29
  Total Volume Baseline                                                                   37.62 (24.91, 58.25)                    23.62 (14.16, 66.35)                 0.61
  **Process Measures**                                                                                                                                                 
  Time from Onset to Baseline CT/CTA (min)                                                74 (62, 90)                             75 (43.75, 101.75)                   0.64
  Time between Baseline CT and Follow-Up CT (min)[^e^](#t001fn006){ref-type="table-fn"}   16.4 (9.3, 25.08)                       19.7 (13.88, 24.88)                  0.75
  Total Hematoma Volume / Time from Onset to Baseline CT, CTA (mL/min)                    0.51 (0.3, 0.71)                        0.38 (0.2, 0.85)                     0.84

Data are n/N (%) or median (25^th^, 75^th^ percentile).

a: N = 26 for arterial phase due to 1 missing value, N = 7 for venous phase due to 1 missing value.

b: N = 22 for arterial phase due to 5 missing values, N = 7 for venous phase due to 1 missing value.

c: N = 26 for arterial phase due to 1 missing value, N = 8 for venous phase.

d: N = 27 for arterial phase, N = 7 for venous phase due to 1 missing value.

e: N = 23 for arterial phase due to 4 missing follow-up CT, N = 7 for venous phase due to 1 missing follow-up CT

TIA = transient ischemic attack, PE = pulmonary embolism, DVT = deep vein thrombosis, mRS = modified Rankin Scale, GCS = Glasgow Coma Scale, NIHSS = National Institutes of Health Stroke Scale, INR = international normalized ratio, ICH = intracerebral hemorrhage, IVH = intraventricular hemorrhage, CTA = CT angiography.

Phases of spot sign appearance are presented in [Table 2](#pone.0236196.t002){ref-type="table"}. Spot signs appeared more frequently in the early arterial and peak arterial phases (62.9%, 14.3%) than in the peak venous and late venous phases (11.4%, 11.4%). Given that there were no spot signs appearing in the equilibrium phase, we pooled the early and peak arterial phases into an arterial cohort, and the peak and late venous phases into a venous cohort, respectively. Higher proportions of significant HE were observed in the arterial phase of spot sign appearance, but these results were not statistically significant (*P* = 0.67).

10.1371/journal.pone.0236196.t002

###### Significant HE across phases of spot sign appearance.

![](pone.0236196.t002){#pone.0236196.t002g}

                                                                       Grouped Arterial Phase   Grouped Venous Phase
  -------------------------------------------------------------------- ------------------------ ----------------------
  **Spot Sign Appearance**[^**a**^](#t002fn001){ref-type="table-fn"}   27/35 (77.1)             8/35 (22.9)
  **Significant HE**[^**b**^](#t002fn002){ref-type="table-fn"}         14/23 (60.9)             3/7 (42.9)

a: Data expressed as N of spot sign appearance in each phase / Total N of spot signs (%).

b: Significant HE defined as ICH growth ≥ 6 mL or ≥ 33% from baseline. Data expressed as N of significant HE / N of spot signs in each phase with follow-up CT (%). Phase determined by spot sign appearance.

The diagnostic accuracy of the phase of spot sign appearance in predicting significant HE is summarized in [Table 3](#pone.0236196.t003){ref-type="table"}. Arterial phase spot sign appearance demonstrated higher sensitivity but lower specificity in predicting significant HE than venous phase. Primary and secondary outcomes are presented in [Table 4](#pone.0236196.t004){ref-type="table"}. Overall, we observed a non-significant trend towards greater proportions of significant HE, in-hospital mortality, poor neurologic status (mRS 4--6) and higher total HE in the arterial cohort. Worst-case and best-case scenarios for sensitivity analyses did not reveal any statistically significant difference in the proportions of significant HE between the arterial and venous phase cohorts (*P* = 1.00 and *P* = 0.22, respectively).

10.1371/journal.pone.0236196.t003

###### Diagnostic accuracy of phase of spot sign appearance in predicting significant HE.

![](pone.0236196.t003){#pone.0236196.t003g}

                                  Grouped Arterial Phase % (95% CI)   Grouped Venous Phase % (95% CI)
  ------------------------------- ----------------------------------- ---------------------------------
  **Sensitivity**                 82 (57--96)                         18 (4--43)
  **Specificity**                 31 (9--61)                          69 (39--91)
  **Positive Predictive Value**   61 (50--70)                         43 (17--74)
  **Negative Predictive Value**   57 (26--83)                         39 (30--50)

10.1371/journal.pone.0236196.t004

###### Radiologic and clinical outcomes across phases of spot sign appearance.

![](pone.0236196.t004){#pone.0236196.t004g}

                                                                     Grouped Arterial Phase   Grouped Venous Phase   P Value
  ------------------------------------------------------------------ ------------------------ ---------------------- ---------
  **Spot Signs**[^**a**^](#t004fn001){ref-type="table-fn"}           27/35 (77.1)             8/35 (22.9)            
  **Significant HE**[^**b**^](#t004fn002){ref-type="table-fn"}       14/23 (60.9)             3/7 (42.9)             0.67
  **Median Total HE**[^**c**^](#t004fn003){ref-type="table-fn"}      10.02 (2.8, 24.1)        4.35 (0.8, 26.6)       0.77
  **Mortality**[^**d**^](#t004fn004){ref-type="table-fn"}            13/27 (48.2)             2/8 (25.0)             0.42
  **Discharge mRS 4--6**[^**e**^](#t004fn005){ref-type="table-fn"}   25/27 (92.6)             5/8 (62.5)             0.07

a: Data expressed as N of spot signs in each phase / Total N of spot signs (%).

b: Significant HE defined as ICH growth ≥ 6 mL or ≥ 33% from baseline. Data expressed as N of significant HE / N of spot signs in each cohort with follow-up CT (%).

c: Total HE defined as the sum of ICH and IVH expansion from baseline. Data expressed as mL (25^th^, 75^th^ percentiles).

d: Data expressed as N of in-hospital mortality / N of spot signs in each cohort (%).

e: Data expressed as N of discharge mRS 4--6 / N of spot signs in each cohort (%).

f: Data expressed as N of mortality or significant HE / N of spot signs in each cohort (%).

Dynamic CTA allowed assessment of contrast extravasation between start and end points of spot sign appearance. We demonstrate the evolution of spot sign formation in arterial phase ([S1 Video](#pone.0236196.s002){ref-type="supplementary-material"}) and in venous phase ([S2 Video](#pone.0236196.s003){ref-type="supplementary-material"}). The median rates of spot sign growth were 0.137 (IQR 0.081--0.399) mL/min and 0.109 (IQR 0.033--0.171) mL/min in the arterial and venous cohorts, respectively.

Discussion {#sec008}
==========

Our findings suggest that dCTA spot signs that appear in the arterial phase have a higher sensitivity but lower specificity to predict HE compared to those that appear in the venous phase. This is consistent with a recent report using conventional CTA acquired in different phases \[[@pone.0236196.ref004]\]. Our study provides further support for this concept by demonstrating a higher rate of contrast extravasation in the arterial phase.

There was an overall non-significant trend towards higher frequencies of significant HE, mortality, discharge mRS 4--6, and greater total HE in the arterial cohort of spot sign appearance. These findings suggest that spot sign appearance in the arterial phase may have higher correlations with significant HE and poor clinical prognosis, but that our study was underpowered to detect statistically significant differences. This is consistent with earlier studies that used repeat CTA or CTA followed by post contrast CT to detect a greater number of spot signs and assess risk of hematoma expansion. Ederies et al. showed that CTA-detected spot signs were more likely associated with HE and poor outcome than post-contrast CT spot signs \[[@pone.0236196.ref008]\]. D'Esterre et al. quantified the contrast leakage rates between these different groups, demonstrating that CTA-detected spot signs had higher contrast leakage rates than post-contrast CT spot signs \[[@pone.0236196.ref009]\]. Brouwers et al. reported that higher spot sign extravasation rates on multiphase CTA were independently associated with greater HE and poorer prognosis \[[@pone.0236196.ref010]\]. Indeed, we observed higher rates of spot sign growth among spot signs appearing in the arterial phase. Altogether, the data suggest that spot signs appearing in the arterial phase may represent faster bleeding, leading to larger HE.

This study is largely exploratory and has limitations. The sample size is small and underpowered to fully evaluate the relationship between the phase of spot sign appearance and clinical outcomes. Furthermore, 15% (4/27) patients were lost to follow-up in the arterial cohort, and 13% (1/8) in the venous cohort. However, our sensitivity analyses did not reveal a change in results. Finally, the calculation of extravasation rates in our study assumes a constant linear relationship between the spot sign volume and the timespan of image acquisition. Emerging automated machine learning measurement techniques may better model extravasation rates in future studies.

Conclusion {#sec009}
==========

The predictability of significant HE and clinical outcome may differ across the timing of spot sign appearance on dCTA. Our results suggest that the majority of spot signs appear in the arterial phase, which has a higher sensitivity to predict HE and poor outcome in ICH. This may be related to higher extravasation rates of arterial phase spot signs, reflecting faster bleeding. Further studies with larger sample sizes are needed to confirm the findings of our study and to better explore the relationship between phase and rate of extravasation.

Supporting information {#sec010}
======================

###### 

(XLSX)

###### 

Click here for additional data file.

###### Dynamic CT angiogram shows temporal evolution of a spot sign that appears in arterial phase in a subject with a large right intraparenchymal frontal hematoma.

The spot sign is located at the 9 o'clock position indicated by the arrow.

(MP4)

###### 

Click here for additional data file.

###### Dynamic CT angiogram shows temporal evolution of a spot sign that appears in venous phase in a subject with a large right intraparenchymal parietal hematoma.

The spot sign is located at the 6 o'clock position indicated by the arrow.

(MP4)

###### 

Click here for additional data file.
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Additional Editor Comments (if provided):

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors examined \'spot sign\' on dynamic CTA\'s (arterial vs. venous phase) ability to predict significant hematoma expansion (defined as 6mL or 33% relative volume growth). This is an important topic as clinical predictors will likely be of value when deciding on trial enrollment for potential therapeutics for ICH. The manuscript is well-written, direct, and easy to follow. The intent of the study is clearly stated and the methods for which the authors attempt to answer their hypothesis is rationale and scientifically sound.

The major limitation of the study is the sample size in each group, in particular the venous phase (n=8), which the authors explicitly mention in the discussion. With this low of a sample size it is challenging to draw a firm conclusion, however, the authors appropriately conclude that the study is \'exploratory\' and \'predictability of significant HE and clinical outcome MAY differ across the timing of spot sign appearance on dCTA\' and \'larger sample sizes are needed to confirm the findings of our study.\' The authors collected subjects prospectively but could consider including retrospective cases if dCTA was being used at their center before they started the study to increase the number of subjects.

Author response: Thank you for your feedback and suggestion. Because our study was prospective, our REB approval was to only collect the data under the protocol funded by the Heart & Stroke Foundation of Canada. It is unlikely they will allow retrospective data collection outside the original protocol, and would require a full new submission and review. While this is not impossible, it would take considerable time for the review (which is often 6 months at our institution). Furthermore, due to COVID, non-COVID submissions are being triaged as low priority, so we are concerned this would further delay reviews.

A few minor requests:

Median time of follow-up CT is listed in the Table however please comment on your sites/study\'s customary practice for serial neuroimaging. For example, repeat CT in all cases within xx h, repeat only if clinically worse.

Author response: Thank you for pointing this out. This has been included in lines 134-135.

Please describe method used to measure hematoma volume (automated segmentation, abc2, etc)

Author response: Thank you, this has been included in lines 135-136.

Reviewer \#2: This article demonstrating a trend towards poor outcome in ICH patients with arterial phase spot sign on dCTA when compared to venous cohorts is well received. The small sample size is mentioned, and publication of this article will highlight the need for further study.

Author response: We thank the reviewer.
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If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors addressed all questions. The reviewer acknowledges the inability of the author to gather retrospective data and does not feel this limitation hinders the work to a point that it should not be shared/published. No further remarks apart from this being a well written manuscript.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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